In a screen of the NCI 60 cancer cell line panel, DLX5 was frequently upregulated in cell lines derived from several tumor types, including ovarian cancer [83], and data from The Cancer Genome Atlas indicate that DLX5 is a poor prognosis marker in ovarian cancer (Figure 8). Here, DLX5 is linked to ovarian carcinoma.